Method
Level · gp.fundamentals.capex_revenue_ratio
Raw value 0.25% · OPTIONAL
· Pharmaceutical Preparations
RESEARCH SNAPSHOTCOLLEGIUM PHARMACEUTICAL, INC's latest supported as-filed period reports revenue of $199.9M; gross margin moved 247 basis points lower on the same comparison basis. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.capex_revenue_ratio
Raw value 0.25% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value 35.68% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value 6.32% · CORE
Level · gp.fundamentals.inventory_revenue_ratio
Raw value 56.67% · OPTIONAL
Level · gp.fundamentals.gross_margin
Raw value 55.18% · CORE
Level · gp.fundamentals.operating_margin
Raw value 1.85% · CORE
Level · gp.fundamentals.sbc_revenue_ratio
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed +10.3% from the comparable as-filed period.
Gross margin changed -247 basis points from the comparable as-filed period.
Gross profit changed +1.8% from the comparable as-filed period.
Inventory changed +196.9% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
COLL · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001104659-26-095464SEC ↗10-QAug 6, 2026Period Jun 30, 20260001628280-26-053851SEC ↗8-KAug 6, 2026Period Aug 6, 20260001628280-26-053849SEC ↗8-K/AJun 30, 2026Period May 12, 20260001104659-26-079323SEC ↗4Jun 10, 2026Period Jun 8, 20260001276038-26-000006SEC ↗4May 20, 2026Period May 18, 20260001296771-26-000004SEC ↗4May 18, 2026Period May 14, 20260001450485-26-000009SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Raw value 7.25% · OPTIONAL
Net income changed -225.6% from the comparable as-filed period.
Operating income changed -89.5% from the comparable as-filed period.
Operating margin changed -1682 basis points from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001606244-26-000002